Loading…
Loading…
Burning Rock Biotech (NASDAQ: BNR - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Volatility and Risk Burning Rock Biotech
On September 30, 2026, Burning Rock Biotech Ltd (BNR) shares fell 6.9% to $17.63, continuing a volatile trading pattern as the stock fluctuated between a 52-wee
On September 25, 2026, Burning Rock Biotech Ltd (BNR) shares rose 3.3% to a current price of $18.60, within a 52-week range of $6.79 to $41.72. This recent upti
GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026.
GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 73,141 of the Company's ADSs for US$618,217.72 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company's insider trading policy.
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2026. Recent Business Updates Early Detection, Therapy Selection & MRD Presented multiple study results at the 2026 AACR in April, showcasing validation data on MMcall, CanCatch Surf, 25-plex ddPCR, and SPIRAL.
GUANGZHOU, China, April 28, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 28, 2026 it filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company's website at http://ir.brbiotech.com.